FDA aprobă o nouă terapie țintită pentru cancerul pancreatic metastatic | Medicamentul a prelungit supraviețuirea într-un studiu clinic

The FDA has approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma, offering a new treatment option. This targeted therapy showed a median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy in a clinical trial. Rasonque targets the RAS protein, crucial in tumor development, and is intended for patients who have received prior systemic therapy or are not candidates for multiple drug treatments. The approval process was expedited, highlighting the urgent need for effective treatments in this aggressive cancer type.